Non-viral, non-integrating plasmid
system for clean iPSCs
Make Transgene-free iPSCs
- Complete mixture with OSK, L-Myc
shRNA-p53, miR302/367 and GFP
- Simple protocol for reliable reprogramming
- Reprogram elderly fibroblast cells efficiently
- Compatible with feeder or feeder-free conditions
Episomal iPSC Reprogramming
Generate Transgene-free iPS Cell Lines Rapidly
The use of four reprogramming factors delivered via retroviral transduction of cells was initially established as a powerful way to reprogram any somatic cell into an ES-like state. These reprogrammed cells are capable of differentiating into any cells representing the three germlines, presenting a system that mirrors human ES cells. While such systems are quite useful for in vitro studies of differentiation, the challenge of adapting these virally-derived iPSCs for in vivo applications (e.g. cell therapy) is quite high, owing to the potential for random integration and subsequent risk of mutagenesis from viral-mediated delivery of reprogramming factors.
SBI has developed and validated a system that uses a non-viral, non-integrating, plasmid-based reprogramming technology and is an unique alternative to traditional retroviral-based reprogramming of cells. SBI's Episomal iPSC Reprogramming system (catalog #SC900A-1), is based on the Epstein-Barr Nuclear Antigen-1 (oriP/EBNA-1) that has been proven to generate iPSCs very efficiently without the risk of transgenic sequences inserted into the target cell genome.
How does the oriP/EBNA-1 system work?
Unlike traditional plasmid systems, the oriP/EBNA-1 system replicates in synchrony with the host genome by anchoring itself to the host chromatin and replicating during the cell cycle divisions. After about 12 cell division cycles, the episomal plasmids are lost leading to the generation of reprogrammed cells without the presence of functional transgenic sequences. SBI's episomal reprogramming kit contains Oct4, Sox2, Klf4, L-myc, Lin28, shRNA-p53, miR302/367 cluster and GFP. These transgene-free iPSCs have the capability to be utilized for a broader range of applications, including pre-clinical research and human gene therapy, thus further delivering on the promise of iPS cells.